BR112021011643A2 - Compostos macrocíclicos e seu uso no tratamento de doença - Google Patents
Compostos macrocíclicos e seu uso no tratamento de doença Download PDFInfo
- Publication number
- BR112021011643A2 BR112021011643A2 BR112021011643-5A BR112021011643A BR112021011643A2 BR 112021011643 A2 BR112021011643 A2 BR 112021011643A2 BR 112021011643 A BR112021011643 A BR 112021011643A BR 112021011643 A2 BR112021011643 A2 BR 112021011643A2
- Authority
- BR
- Brazil
- Prior art keywords
- thia
- diaza
- trifluoromethyl
- dipyridine
- dioxide
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D419/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms
- C07D419/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
- C07D513/18—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains four or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D515/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D515/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
- C07D515/18—Bridged systems
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862783270P | 2018-12-21 | 2018-12-21 | |
| US62/783,270 | 2018-12-21 | ||
| PCT/IB2019/061054 WO2020128925A1 (en) | 2018-12-21 | 2019-12-18 | Macrocyclic compounds and their use in the treatment of disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112021011643A2 true BR112021011643A2 (pt) | 2021-09-08 |
Family
ID=69165443
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112021011643-5A BR112021011643A2 (pt) | 2018-12-21 | 2019-12-18 | Compostos macrocíclicos e seu uso no tratamento de doença |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20220071971A1 (https=) |
| EP (1) | EP3898621A1 (https=) |
| JP (1) | JP2022513959A (https=) |
| KR (1) | KR20210107046A (https=) |
| CN (1) | CN113227087A (https=) |
| AU (1) | AU2019404934B2 (https=) |
| BR (1) | BR112021011643A2 (https=) |
| CA (1) | CA3119656A1 (https=) |
| MX (1) | MX2021007592A (https=) |
| WO (1) | WO2020128925A1 (https=) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2019222758B2 (en) | 2018-02-15 | 2022-07-07 | Vertex Pharmaceuticals Incorporated | Macrocycles as modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions thereof, their use in the treatment of cystic fibrosis, and process for making them |
| TWI848092B (zh) | 2019-04-03 | 2024-07-11 | 美商維泰克斯製藥公司 | 囊腫纖維化跨膜傳導調節蛋白調節劑 |
| CA3150162A1 (en) | 2019-08-14 | 2021-02-18 | Vertex Pharmaceuticals Incorporated | Crystalline forms of cftr modulators |
| TWI899097B (zh) | 2019-08-14 | 2025-10-01 | 美商維泰克斯製藥公司 | 製備cftr調節劑之方法 |
| TWI867024B (zh) | 2019-08-14 | 2024-12-21 | 美商維泰克斯製藥公司 | 囊腫纖維化跨膜傳導調節蛋白之調節劑 |
| WO2022194399A1 (en) | 2020-07-13 | 2022-09-22 | Idorsia Pharmaceuticals Ltd | Macrocycles as cftr modulators |
| CR20230120A (es) * | 2020-08-07 | 2023-09-01 | Vertex Pharma | Moduladores del regulador de la conductancia transmembrana de la fibrosis quística |
| IL300413A (en) | 2020-08-13 | 2023-04-01 | Vertex Pharma | Crystal forms of CFTR modulators |
| EP4225762A1 (en) | 2020-10-07 | 2023-08-16 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
| EP4225765A2 (en) * | 2020-10-07 | 2023-08-16 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
| EP4225447A1 (en) * | 2020-10-07 | 2023-08-16 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
| MX2023004074A (es) * | 2020-10-07 | 2023-07-05 | Vertex Pharma | Moduladores del regulador de la conductancia transmembrana de la fibrosis quistica. |
| AU2021397294A1 (en) | 2020-12-10 | 2023-07-06 | Vertex Pharmaceuticals Incorporated | Methods of treatment for cystic fibrosis |
| EP4308575A1 (en) * | 2021-03-16 | 2024-01-24 | Idorsia Pharmaceuticals Ltd | Macrocycles as cftr modulators |
| TWI904194B (zh) * | 2021-07-12 | 2025-11-11 | 瑞士商愛杜西亞製藥有限公司 | 作為cftr調節劑之巨環 |
| IL315715A (en) * | 2022-04-06 | 2024-11-01 | Vertex Pharma | Modulators of cystic fibrosis transmembrane conductance regulation |
| TW202421102A (zh) | 2022-09-15 | 2024-06-01 | 瑞士商愛杜西亞製藥有限公司 | 巨環cftr調節劑與cftr校正子及/或cftr增效劑之組合 |
| CA3267791A1 (en) | 2022-09-15 | 2024-03-21 | Idorsia Pharmaceuticals Ltd | CRYSTALLINE FORM OF (3S,7S,10R,13R)-13-BENZYL-20-FLUORO-7-ISOBUTYL-N-(2-(3-METHOXY-1,2,4-OXADIAZOL-5-YL)ETHYL)-6,9-DIMETHYL-1,5,8,11-TETRAOXO-10-(2,2,2-TRIFLUOROETHYL)-1,2,3,4,5,6,7,8,9,10,11,12,13,14-TETRADECAHYDRO-[1]OXA[4,7,10,14]TETRAAZACYCLOHEPTADECINO [16,17-F]QUINOLINE-3-CARBOXAMIDE |
| KR20250084132A (ko) | 2022-09-15 | 2025-06-10 | 이도르시아 파마슈티컬스 리미티드 | 마크로시클릭 cftr 조절제 |
| CN115498160B (zh) * | 2022-09-29 | 2025-09-30 | 郑州大学 | 一种锂-有机硫电池正极材料及其制备方法和应用 |
| WO2025186214A1 (en) | 2024-03-05 | 2025-09-12 | Idorsia Pharmaceuticals Ltd | Macrocyclic cftr modulators |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9617282B2 (en) * | 2013-03-15 | 2017-04-11 | Biogen Ma Inc. | Macrocyclic compounds as IRAK4 inhibitors for the treatment of inflammatory diseases |
| WO2015138934A1 (en) * | 2014-03-13 | 2015-09-17 | Proteostasis Therapeutics, Inc. | Compounds, compositions, and methods for increasing cftr activity |
| US9981945B2 (en) * | 2015-10-07 | 2018-05-29 | NuBridge BioSciences | Pyrimidine derivatives as CFTR modulators |
| TW201811766A (zh) * | 2016-08-29 | 2018-04-01 | 瑞士商諾華公司 | N-(吡啶-2-基)吡啶-磺醯胺衍生物及其用於疾病治療之用途 |
| EP3580224B1 (en) * | 2017-02-07 | 2022-07-13 | Biogen MA Inc. | Ask1 inhibiting agents |
| AU2019222758B2 (en) * | 2018-02-15 | 2022-07-07 | Vertex Pharmaceuticals Incorporated | Macrocycles as modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions thereof, their use in the treatment of cystic fibrosis, and process for making them |
-
2019
- 2019-12-18 CA CA3119656A patent/CA3119656A1/en active Pending
- 2019-12-18 EP EP19836572.8A patent/EP3898621A1/en not_active Withdrawn
- 2019-12-18 BR BR112021011643-5A patent/BR112021011643A2/pt not_active IP Right Cessation
- 2019-12-18 JP JP2021534681A patent/JP2022513959A/ja active Pending
- 2019-12-18 CN CN201980083703.6A patent/CN113227087A/zh active Pending
- 2019-12-18 US US17/415,335 patent/US20220071971A1/en not_active Abandoned
- 2019-12-18 AU AU2019404934A patent/AU2019404934B2/en not_active Ceased
- 2019-12-18 MX MX2021007592A patent/MX2021007592A/es unknown
- 2019-12-18 WO PCT/IB2019/061054 patent/WO2020128925A1/en not_active Ceased
- 2019-12-18 KR KR1020217022294A patent/KR20210107046A/ko not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| AU2019404934A1 (en) | 2021-06-03 |
| CN113227087A (zh) | 2021-08-06 |
| EP3898621A1 (en) | 2021-10-27 |
| WO2020128925A1 (en) | 2020-06-25 |
| JP2022513959A (ja) | 2022-02-09 |
| KR20210107046A (ko) | 2021-08-31 |
| US20220071971A1 (en) | 2022-03-10 |
| CA3119656A1 (en) | 2020-06-25 |
| AU2019404934B2 (en) | 2022-04-21 |
| MX2021007592A (es) | 2021-08-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112021011643A2 (pt) | Compostos macrocíclicos e seu uso no tratamento de doença | |
| JP2022513959A5 (https=) | ||
| ES2838977T3 (es) | Inhibidores de la lisil oxidasa fluorada tipo 2 y usos de los mismos | |
| ES2898069T3 (es) | Derivados de N-(piridin-2-il)piridinosulfonamida y su uso en el tratamiento de la enfermedad | |
| AU2020374957A1 (en) | Small molecule degraders of Helios and methods of use | |
| US20230119547A1 (en) | Di-substituted pyrazole compounds for the treatment of diseases | |
| CN104725359B (zh) | 取代的哌嗪化合物及其使用方法和用途 | |
| WO2021078301A1 (zh) | 蛋白降解剂及其在疾病治疗中的应用 | |
| ES2821400T3 (es) | Compuestos de 6-heterociclil-4-morfolin-4-ilpiridin-2-ona útiles para el tratamiento del cáncer y la diabetes | |
| JP2019501142A (ja) | Ｕｓｐ３０の阻害剤としての１−シアノピロリジン誘導体 | |
| US20220127247A1 (en) | N-(pyridin-2-yl)pyridine-sulfonamide derivatives and their use in the treatment of disease | |
| US9809568B2 (en) | Compounds inhibiting leucine-rich repeat kinase enzyme activity | |
| CN103917534B (zh) | 作为h3受体抑制剂的包含哌啶和哌嗪环的氨基甲酸酯/脲衍生物 | |
| CN105085482B (zh) | 取代的哌嗪化合物及其使用方法和用途 | |
| WO2023215471A1 (en) | Tetrahydroisoquinoline heterobifunctional bcl-xl degraders | |
| WO2020020377A1 (zh) | 用作fgfr4抑制剂的稠环衍生物 | |
| RU2804139C2 (ru) | Макроциклические соединения и их применение в лечении заболевания | |
| JP2023509496A (ja) | ＲＯＲγｔ阻害剤、その製造方法及び使用 | |
| CN106065018A (zh) | 取代的吲哚化合物及其使用方法和用途 | |
| WO2025042896A1 (en) | DNA TOPOISOMERASE IIβ INHIBITORS | |
| AU2015200638B2 (en) | Pyrazolo [1, 5 -a] pyrimidines as antiviral agents | |
| TW202430501A (zh) | 醯基磺胺化合物作為多瘤病毒的抑制劑 | |
| HK40063935A (zh) | 多环tlr7/8拮抗剂及其在治疗免疫失调中的用途 | |
| BR112020006456A2 (pt) | compostos químicos | |
| BR112020006456B1 (pt) | Compostos químicos, composição farmacêutica e seus usos para tratar uma infecção por vírus da hepatite b e para inibir o nível do antígeno hbe ou hbs em um hbsag de mamífero in vitro |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] | ||
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 6A ANUIDADE. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2859 DE 21-10-2025 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |